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ObituaryStanley J. KorsmeyerThe scientific community has been saddened and di-
minished by the loss of Stanley J. Korsmeyer, M.D.,
who died of lung cancer last month at the age of 54.
Over the last 25 years, Korsmeyer had been an interna-
tional leader in the fields of cancer biology and pro-
grammed cell death (apoptosis). Through his studies of
apoptosis, Korsmeyer helped revolutionize our con-
cepts of carcinogenesis. Korsmeyer, a medical oncolo-
gist by training, also helped translate this knowledge
into the development of novel cancer therapeutics that
are just now entering into human clinical trials.
Stan didn’t start out to be a research scientist. He
grew up the oldest of four on a livestock farm in south-
ern Illinois. It was his involvement in the 4-H club that
spawned his interest in science. From the beginning,
his scientific experiments met with success. The pair
of Hampshire Hogs he raised at age 14 were named
Grand Champion at the Illinois State Fair, and Stan
went off to the University of Illinois determined to be-
come a veterinarian. However, on the advice of one of
his veterinary mentors, he switched to pre-med. Fol-
lowing receipt of an M.D. degree from the University
of Illinois and an internship and residency at UCSF, he
arrived at the NIH as a Research Fellow at a time when
molecular biology was just beginning to revolutionize
the study of human disease. There, under the tutelage
of scientists like Tom Waldmann and Phil Leder, Stan
soon joined the vanguard of research scientists charac-
terizing the molecular features of the chromosomal
translocations that had been observed in patients with
leukemia/lymphoma. Over his career, Stan contributed
to the characterization of a variety of chromosomal
translocations and identified several widely studied on-
cogenes including MLL, AF-4, and Ttg-1 (rhombotin).
Although he had many accomplishments, Stan will
be best known for his contributions to the discovery
and characterization of the role that programmed cell
death plays in the pathogenesis of cancer. In 1985, the
Korsmeyer laboratory was one of three laboratories to
describe the molecular aspects of a chromosomal
translocation between chromosomes 14 and 18 ob-
served in the majority of patients with follicular lym-
phoma. This translocation placed the immunoglobulin
gene enhancer from chromosome 14 in close proximity
to a previously uncharacterized gene on chromosome
18 that was given the name Bcl-2. From the beginning,
Bcl-2 was a problem. It didn’t score easily in any of
the assays usually used to characterize oncogenes. In
1988, a group from The Walter and Eliza Hall Institute
reported that Bcl-2 could promote the survival of
hematopoietic cells in culture. Shortly thereafter, Kors-
meyer, who had been pursuing an independent investi-
gation to determine whether Bcl-2 overexpression
could alter B cell development and/or transformation
in vivo, confirmed and extended this observation. Kors-
meyer demonstrated that a Bcl-2 transgene expressed
under the control of an immunoglobulin enhancer led
to the progressive accumulation of B cells in vivo. TheStanley J. Korsmeyertransgenic B cells were characterized by an extended
cell survival, and this extended survival led ultimately
to an increased incidence of B cell lymphomas in the
mice. These studies provided the first evidence that in-
hibiting cell death by apoptosis could contribute to de-
velopment of cancer.
Following his pioneering discoveries of the role of
Bcl-2 in preventing programmed cell death and in pro-
moting carcinogenesis, Stan remained at the forefront
of apoptosis research. Not only did he demonstrate that
overexpression of Bcl-2 could enhance lymphocyte sur-
vival in vivo, he also demonstrated that Bcl-2s’ endoge-
nous role was to regulate cell survival. He showed that
Bcl-2-deficient mice were unable to maintain the sur-
vival of mature lymphocytes. Bcl-2-deficient animals
developed profound immunodeficiency soon after
birth. Korsmeyer also led investigations to identify how
Bcl-2 proteins work. His laboratory localized Bcl-2 to
the mitochondria; discovered Bax, a Bcl-2 homolog
whose function was to execute cells rather than keep
cells alive; and cloned Bad and Bid, two BH3-only-con-
taining Bcl-2 homologs that modulate the functions of
other family members. In recent years, many others
Cell
320have contributed to the current understanding of apo- A
ptosis regulation, but Stan continued to be a leading r
figure. As the Bcl-2 family expanded to include a dizzy- D
ing array of death inhibitors and death effectors and C
their intermolecular regulatory network became increas- s
ingly complex, it was Stan who came up with a simple P
model of Bcl-2 function that focused on the family’s H
central activity. Stan proposed that the combined activ- d
ities of Bcl-2-related proteins acted like a rheostat to t
regulate a cell’s sensitivity to apoptotic stimuli. He c
hoped to take advantage of this by developing cancer C
therapeutics specifically designed to either inhibit the h
antiapoptotic members or activate the proapoptotic l
members. o
Stan’s ability to reduce problems to first principles
Ckept the field’s attention focused on the big picture.
Stan’s summation to a science writer of his interest in A
the Bcl-2 family said it best: “It turns out to be a family D
in which there are good guys and bad guys.” Last year, R
Stan’s laboratory collaborated with investigators in the U
Harvard Chemistry Department to develop peptide mi- 4
metics of the BH3 proteins that suppress the antiapo- P
ptotic function of Bcl-2. Using a chemical technique *
called hydrocarbon stapling, they replaced the natural
amino acids within a BH3 peptide sequence to produce
a stable helical structure with enhanced killing activity
and provided preliminary evidence that treatment of
cultured leukemia cells with these modified peptides
led to selective inhibition of leukemic cell survival.
Treatment of mice with leukemia with these new com-
pounds slowed disease progression. In addition, Stan’s
collaboration with a company he helped found, Idun
Pharmaceuticals, and Abbott Laboratories has led to
the development of small molecule inhibitors of anti-
apoptotic Bcl-2 proteins. These mimetics appear to
shift the Bcl-2 rheostat in favor of the proapoptotic
family members and induce programmed cell death in
cancer cells with elevated levels of antiapoptotic Bcl-
2-related proteins. Ironically, in a paper soon to be pub-
lished, these new Bcl-2 inhibitors are shown to have
single agent activity in treating lung cancer cells.
As numerous and significant as Stan’s scientific
achievements were, what those of us who worked with
him will remember is the enthusiasm and perspective
that he brought to his research. No matter how compet-
itive the situation, he always reminded his own labora-
tory, collaborators, and competitors that the important
goal was to focus on developing a deeper understand-
ing of cancer and utilize that information to improve
cancer treatment. Stan’s dedication to science was sur-
passed only by his dedication and love for his family.
Despite being a nonsmoker, he developed lung cancer.
Even his illness couldn’t change his approach to life.
Right through the final stages of his treatment, he faced
his illness with courage and optimism, actively partici-
pating in the choice of therapy he received. Stan was
never one to stay on the sidelines.
Stan’s contributions to cancer research were recog-
nized widely in his lifetime. He was appointed a tenured
Professor, first at Washington University and then at
Harvard. Stan was appointed an Investigator within the
Howard Hughes Medical Institute at both universities.
He was elected to membership of the National Acad-
emy of Sciences, the Institute of Medicine, and themerican Philosophical Society. His awards for cancer
esearch include the Bristol Meyers Squibb Award for
istinguished Achievement in Cancer Research, the
harles S. Mott Prize of General Motor Cancer Re-
earch Foundation, the 2000 Louisa Gross Horwitz
rize, the Stratton Medal from the American Society of
ematology, the Leukemia and Lymphoma Society
eVilliers International Achievement Award, and the In-
ernational Award for Cancer Research from the Pez-
oller Foundation and the American Association for
ancer Research. Nevertheless, those of us who knew
im will remember Stan best for his qualities as a col-
eague, mentor, and friend. When Stan Korsmeyer died
n March 31, 2005, we lost one of the good guys.
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